These 96-well plates are pre-configured with the most appropriate TaqMan® Gene Expression Assays for a specific biological process, pathway, or disease state. Each plate contains predefined assays and endogenous controls dried-down in the wells, ready for accurate assessment of an entire gene signature in one simple experiment. The panel of assays in the TaqMan® Array 96-well Human Alzheimer's Disease Plate is based on the 'amyloid hypothesis’. The 92 genes are involved in APP processes that generate beta-amyloid and included genes implicated in multiple secondary steps of beta-amyloid aggregation, tau hyperphosphorylation, excitotoxicity, inflammation, oxidation and microglial activation. We also include assays for genes involved in cholesterol biosynthesis due to the correlation between high cholesterol and increased risk of Alzheimer's. Genes associated with Alzheimer's disease pathology, biochemistry and genetics are also included.